                              In the
 United States Court of Appeals
               For the Seventh Circuit
                          ____________

No. 02-3740
COOK INC.,
                                                   Plaintiff-Appellant,
                                  v.

BOSTON SCIENTIFIC CORPORATION,
                                                  Defendant-Appellee.
                          ____________
             Appeal from the United States District Court
        for the Northern District of Illinois, Eastern Division.
           No. 01 C 9479—Charles P. Kocoras, Chief Judge.
                          ____________
        ARGUED APRIL 16, 2003—DECIDED JUNE 19, 2003
                          ____________


  Before POSNER, COFFEY, and ROVNER, Circuit Judges.
   POSNER, Circuit Judge. The plaintiff brought suit seek-
ing a declaration that it had not violated a contract to which
it and the defendant, along with a third firm, are parties.
Jurisdiction is based on diversity of citizenship, and the
governing substantive law is that of the state of Washing-
ton, though no peculiarities of Washington law have been
drawn to our attention. The defendant counterclaimed,
charging that the plaintiff had indeed broken the con-
tract. On cross-motions for summary judgment, the dis-
trict court ruled for the defendant and entered a perma-
nent injunction against the plaintiff, precipitating this ap-
peal.
2                                                 No. 02-3740

   The contract involves a medical device known as a stent.
The narrowing of an artery, as by atherosclerosis, is called
“stenosis” and one way of treating it is by balloon angio-
plasty, a procedure in which a small balloon is inserted
into the affected artery to press against the wall of the
artery, restoring the artery to its normal dimensions. The
stent is a metal tube that encloses the balloon and re-
mains in the artery after the procedure. Yet sometimes
despite the stent the stenosis reappears—this is called
“restenosis”—and there is medical opinion that the like-
lihood of this happening can be reduced by coating
the stent with a suitable drug. One candidate to be such
a drug is paclitaxel, which gained fame as an anticancer
drug under the trade name Taxol. The patent rights for
use of paclitaxel on stents are held by a Canadian com-
pany called Angiotech Pharmaceuticals. Angiotech does
not manufacture either stents or drugs, and so it decided
to license the use of paclitaxel for coating stents. It granted
“coexclusive” licenses to Cook Incorporated and Boston
Scientific Corporation (BSC), firms involved in the de-
velopment of drug-coated stents for preventing restenosis.
Each license grants the licensee “worldwide right[s] and
license to use, manufacture, have manufactured, distrib-
ute and sell, and to grant sublicenses to its Affiliates to
use, manufacture, have manufactured, distribute and sell
[paclitaxel] . . . solely for use in [stents].” The licenses
are exclusive in the sense that Angiotech promises not
to license the use of paclitaxel for coating stents to any
other firm, but coexclusive in the sense that each li-
censee has the same rights. Critically, the licenses forbid
the licensee to assign his license, or to grant a sublicense
to anyone except an affiliate, unless all parties to the two
licenses, which is to say Angiotech, BSC, and Cook, agree.
We’ll call this provision the “anti-assignment” clause,
although it covers sublicenses as well. Why the distinction
No. 02-3740                                                 3

between assignment to an affiliate, which is forbidden,
and sublicensing an affiliate, which is permitted, is un-
clear, since, while an assignment and a sublicense are not
identical, a sublicense can be drafted in such a way as to
have the same effect. Finance Investment Co. v. Geberit AG,
165 F.3d 526, 531-32 (7th Cir. 1998); Black Clawson Co. v.
Kroenert Corp., 245 F.3d 759, 765 (8th Cir. 2001); Prima Tek
II, L.L.C. v. A-Roo Co., 222 F.3d 1372, 1377 (Fed. Cir. 2000).
  The two licenses were granted in a single contract, so
that both the licensees and Angiotech are contractually
bound to one another. The contract provides for the ar-
bitration of disputes arising under it, but the parties have
waived that provision. Angiotech is not a party to this
suit; it may be indifferent to the outcome or reluctant to
take sides in a dispute between its most important part-
ners in the development of restenosis-resisting stents.
   Why coexclusive licenses? No evidence has been pre-
sented or arguments made concerning the reason for the
coexclusive feature. The lawyers either have not bothered
to inquire or have not bothered to inform us or the dis-
trict judge concerning the commercial setting of such a
contract. They seem insensitive to the importance to the
sound interpretation of contracts of understanding the
business purpose served by a contract’s provisions, and
to the limitations of generalist judges’ knowledge of the
customs and practices of specific industries. We are left to
speculate, having found no secondary literature on coex-
clusive licenses either.
  A patentee’s choice between granting exclusive and
nonexclusive licenses is similar to a seller’s choice between
granting exclusive and nonexclusive rights to his dealers.
The dealer who is granted an exclusive right will have
an enhanced incentive to devote his sales efforts to the
seller’s product. Dealers who do not receive exclusive rights
4                                                 No. 02-3740

will have enhanced incentives to minimize their margins
by competing among themselves, thus maximizing the
price that the seller can charge. Consumers’ demand is a
function of the dealer’s as well as the original seller’s
profit margin. For both margins are components of the
retail price, and so the lower the dealer’s margin is, the
lower that price will be, the more therefore will be sold,
and so the greater will be the original seller’s total profits.
   Thus a patentee can ordinarily be expected either to
grant nonexclusive licenses in order to exploit the effect
of competition in minimizing the licensees’ margins or
to grant an exclusive license in order to encourage the
licensee to invest in the further development of the li-
censed process or product by protecting the licensee from
the competition of other licensees, which might prevent
the licensee from recouping his investment. John W.
Schlicher, Licensing Intellectual Property: Legal, Business,
and Market Dynamics 69-71 (1996). There are other con-
siderations bearing on the choice between exclusive and
nonexclusive licensing as well, see, e.g., Michael L. Katz
& Carl Shapiro, “How to License Intangible Property,” 101
Q.J. Econ. 567 (1986); Carl Shapiro, “Patent Licensing and
R&D Rivalry,” Am. Econ. Rev. Papers & Proceedings, May
1985, pp. 25, 27, but we needn’t get into them.
   The second goal that we have mentioned, that of encour-
aging investment by the licensee, is the relevant one in
this case. Angiotech does not manufacture or coat stents
itself. It depends on its licensees to develop the product
(that is, the coated stents) and obtain the Food and Drug
Administration’s approval so that the product can be
marketed. If, therefore, Cook or BSC were essentially
interchangeable, or one were clearly a superior developer
to the other, we would expect Angiotech to grant an ex-
clusive license to one of them. Probably the reason it did
No. 02-3740                                               5

not is that the two firms use different coating methods,
requiring each to obtain separate approval from the Food
and Drug Administration before being permitted to mar-
ket a drug-coated stent in the United States. When the
contract was made, and indeed to this day, neither Cook
nor BSC had yet obtained FDA approval. Their products
are still being tested for safety and efficacy. Angiotech
would not have wanted to risk betting on the wrong
horse—granting BSC an exclusive license, for example,
when Cook’s stent might turn out to be the only drug-
coated stent that the FDA would approve, or might be
approved earlier than BSC’s product, or might prove to be
the superior product.
  At the same time—and here we approach the crux of the
appeal—Cook and BSC might be reluctant to accept nonex-
clusive licenses. To obtain FDA approval for a new drug
or medical device (a paclitaxel-coated stent is what the
FDA calls a “combination product” and is assigned to
the division of FDA that handles devices) requires a sub-
stantial investment, which the manufacturer of the de-
vice might have difficulty recouping if it faced competi-
tion from another licensee. With Angiotech reluctant to
grant an exclusive license and Cook and BSC reluctant to
settle for nonexclusive licenses, coexclusive licenses were
a natural compromise.
  The compromise might be undone by assignment or
sublicensing. Suppose Cook fell behind BSC in the race
to develop an approved and marketable paclitaxel-coated
stent and tried to recover the lead by assigning its license
to a firm with greater resources or other advantages that
would enable it to overtake BSC. The effect would be to
confront the latter with more competition than it had
reckoned on when it took out its license from Angiotech.
Hence the bar on assignment without the permission of
6                                               No. 02-3740

the other licensee (plus Angiotech, though that is not a
factor here). Although competition is generally a good
thing, there is no argument that Angiotech would have
violated antitrust law or been guilty of patent misuse had
it granted an exclusive, nonassignable license. And so we
cannot see how Angiotech’s action in granting two licenses
and forbidding the licensees to increase the number of
competitors by means of assignment or sublicensing
could raise an antitrust or patent-misuse issue. Notice
that the licenses do not forbid the acquisition of the li-
censee by another firm—to which as an affiliate the li-
censee could grant a sublicense without obtaining the
permission of the other parties to the contract with
Angiotech—that might be a more formidable competitor
of the other licensee.
   Angiotech granted the coexclusive licenses in 1997.
Four years later Cook made a contract (actually five simul-
taneous contracts, but that is a detail of no legal signifi-
cance) with Advanced Cardiovascular Systems, Inc. (ACS),
a manufacturer of medical devices and a subsidiary of
Guidant Corporation. Under the contract, Cook is to
purchase stents from ACS, coat them with paclitaxel, and
sell the coated stents back to ACS for resale to hospitals
and other purchasers of medical devices. The price re-
ceived by Cook for the stents that it sells to ACS is to be
one-third of the resale price charged by ACS. Before re-
selling the stents to hospitals or other users of stents, ACS
is to mount them on a catheter (which it manufactures)
for inserting the balloon and stent into the artery. So what
it is selling is really a stent system rather than merely a
stent. The stent system is called “ACHIEVE,” an ACS
brand, though Cook’s name will also appear on the pack-
age. The contract requires ACS to obtain the regulatory
rulings necessary to enable ACHIEVE stent systems ac-
tually to be sold, such as approval by the FDA.
No. 02-3740                                                   7

  BSC argues and the district judge found that the trans-
action between Cook and ACS is a de facto assignment
and so violates the contract because BSC did not consent.
(ACS like Angiotech is not a party to the suit—which is
a surprise, as one might have expected BSC to join ACS
as a counterdefendant on the theory that ACS committed
the tort of interference with BSC’s contract with Angio-
tech and Cook.) Cook argues that since the finding was
made in a summary judgment proceeding rather than
after a trial, we should review it de novo, that is, without
according any deference to the district judge’s ruling. This
is a strange argument. A judge makes findings in a trial
or other evidentiary hearing; a grant of summary judgment
is a determination that there are no triable issues. So one
would expect Cook to be asking not for de novo review
of the district judge’s findings, but for a trial. One possibil-
ity is that Cook thinks (incorrectly, as we’ll see) that the
question whether the de facto assignment violated the
contract is a pure question of law. Another is that Cook
consented to have the district judge decide the question
of contractual violation on the basis of the pleadings,
the briefs, and the limited discovery that had been con-
ducted before the motion for summary judgment was
made. Both inferences are supported by Cook’s opposi-
tion to BSC’s completing discovery.
  When litigants waive trial, and ask the judge to decide
the case as if the record compiled in the pretrial proceed-
ings were a trial record, appellate review is as of find-
ings made after a trial, not as of a grant of summary judg-
ment. “[S]ometimes both parties move for summary judg-
ment because they do not want to bear the expense of trial
but instead want the trial judge to treat the record of the
summary judgment proceeding as if it were the trial rec-
ord. In effect the judge is asked to decide the case as if
there had been a bench trial in which the evidence was
8                                                 No. 02-3740

the depositions and other materials gathered in pretrial
discovery.” May v. Evansville-Vandenburgh School Corp., 787
F.2d 1105, 1115 (7th Cir. 1986); see also Hess v. Hartford
Life & Accident Ins. Co., 274 F.3d 456, 461 (7th Cir. 2001). It
is true that the mere fact that cross-motions for summary
judgment are filed, as was done in this case, does not
operate as a waiver of the right to a trial. Miller v. LeSea
Broadcasting, Inc., 87 F.3d 224, 230 (7th Cir. 1996). But
though there was no explicit waiver, it is reasonably clear
that Cook didn’t want a trial (more precisely, it either
wanted a trial limited to the summary judgment record
or thought the issue of contractual violation could be
resolved without a factual record) and so waived its right
to a (fuller) trial. In its opening brief on appeal, Cook
belatedly requested a trial if summary judgment in its
favor was rejected. BSC replied that the demand comes
too late—and Cook apparently agrees, for its reply brief
is silent on the point: a second waiver.
   The interpretation of a written contract, when no ex-
trinsic evidence (evidence other than the contract itself)
is presented, is treated as an issue of law, and thus is
decided by the appellate court de novo, that is, without
giving the trial judge’s interpretation any special weight.
But the rule is otherwise when as in this case the resolu-
tion of the interpretive issue requires a comparison of
written documents and thus an inference from multiple
pieces of evidence, a traditional task of a finder of fact,
rather than requiring merely “gazing” at a single document.
Coplay Cement Co. v. Willis & Paul Group, 983 F.2d 1435, 1438
(7th Cir. 1993). (The comparison required in this case is
between the three-cornered Angiotech licensing contract
with Cook and BSC and Cook’s contract with ACS.) In
such a case the ruling of the trier of fact is reversible only
if clearly erroneous. E.g., In re Modern Dairy of Champaign,
Inc., 171 F.3d 1106, 1109 (7th Cir. 1999); Glass v. Kemper
No. 02-3740                                                   9

Corp., 133 F.3d 999, 1001 (7th Cir. 1998). No matter. The
district judge’s ruling was not erroneous at all, and so
the precise standard of review is unimportant.
  Had the contract between Cook and ACS provided that
Cook would license to ACS the use of paclitaxel in the
ACHIEVE stent system, this would have been an assign-
ment or sublicense in violation of the anti-assign-
ment clause; and as that part of the contract was in-
tended, in part anyway, to protect BSC, BSC has a right
to enforce it. (It would have a right to enforce it, as a third-
party beneficiary, even if it were not a party to the con-
tract. See A.E.I. Music Network, Inc. v. Business Computers,
Inc., 290 F.3d 952, 955-56 (7th Cir. 2002); Vidimos, Inc.
v. Laser Lab Ltd., 99 F.3d 217, 219-20 (7th Cir. 1996);
Postlewait Construction, Inc. v. Great American Ins. Cos., 720
P.2d 805, 806-07 (Wash. 1986).) This conclusion would
be unaffected if besides licensing the use of paclitaxel to
coat ACS’s ACHIEVE stents, Cook had agreed to do the
coating itself (as it did agree in its “sale” contracts with
ACS). Cook would still be licensing the distribution
and sale of paclitaxel in stents to ACS, a firm with which
Cook is not affiliated.
   This means that Cook’s defense to BSC’s charge of
breach of contract hinges on the fact that Cook is to sell
the coated stents to ACS rather than assigning its patent
license to ACS. Cook describes the “sale” as the exercise
of the right granted to it by Angiotech to distribute and
sell Angiotech’s patented product. But the sale of ACS’s
stents back to ACS has no commercial purpose or sub-
stance; it is merely a device for defeating the anti-assign-
ment clause. (By the way, no supposed public policy against
anti-assignment clauses is invoked by Cook. Com-
pare Bank of America, N.A. v. Moglia, No. 02-2517, 2003
WL 21254909, at *5 (7th Cir. June 2, 2003).) Suppose a Mr.
10                                              No. 02-3740

Guidant asks a Mr. Cook to paint his house. And Cook
says, fine, but let’s do it this way: you sell me your house,
I’ll paint it (supplying both the paint and the labor to
apply the paint to the house), and then I’ll sell the house,
painted, back to you. That would make no commercial
sense, and so one would delve for an improper mo-
tive. Confronted at argument by the housepainting hy-
pothetical, Cook’s lawyer was unable to distinguish it
from this case.
   It is obvious what is going on. Cook wanted to improve
its competitive posture vis-à-vis BSC by obtaining the
resources of a firm that had a better stent than Cook it-
self. It could have done so without breaking its contract,
by affiliating with ACS; affiliation, as by the sale of Cook
to Guidant (a transaction actually contemplated at one
point, as we’ll see), would have allowed Cook to grant
a sublicense to ACS. This would not have been an eva-
sion of the three-cornered contract, because the sublicens-
ing of an affiliate is authorized by the licenses. It might
appear to be a case of taking advantage of a loophole,
but maybe not; it is more costly to merge with another
firm than to execute an assignment or the series of five
contracts that in substance were an assignment. We know
it’s easier because after the district court enjoined the
assignment, Cook entered into merger discussions with
Guidant, which failed; had they succeeded, the cost to
Guidant would have been in the neighborhood of $3 billion.
  But while a merger plus an assignment or a sublicense
differs in substantial and not merely formal respects
from an assignment, the five contracts between Cook and
ACS, realistically treated as one, differ from an assign-
ment only in formal, in the sense of economically empty,
respects. See In re Shulman Transport Enterprises, Inc., 744
F.2d 293, 295 (2d Cir. 1984); cf. Grojean v. Commissioner,
No. 02-3740                                              11

248 F.3d 572, 574 (7th Cir. 2001); SEC v. SG Ltd., 265 F.3d
42, 46-47 (1st Cir. 2001). Not that sale-and-leaseback ar-
rangements, which the Cook-ACS transaction superfi-
cially resembles, are characteristically devoid of economic
substance, though they can be, as in Coleman v. Commis-
sioner, 16 F.3d 821, 826-27 (7th Cir. 1994), since a common
purpose is to give the buyer-lessor tax benefits, see,
e.g., Solargistic Corp. v. United States, 921 F.2d 729, 730
(7th Cir. 1991). But emphasis falls on “superficially.”
Cook didn’t buy stents from ACS and then lease them
back; it bought them from ACS and then resold them to
ACS, the only purpose of the transaction being to trans-
fer Cook’s patent rights to ACS in circumvention of the
anti-assignment clause.
  A further issue discussed in the briefs is whether Cook
also violated a clause in the contract that makes it respon-
sible for obtaining the necessary regulatory approvals
for the sale of a paclitaxel-coated stent. BSC argues that
Cook shifted that responsibility to ACS, and Cook replies
that it retained ultimate responsibility and anyway that
Angiotech hardly cares whether Cook or ACS takes the
laboring oar in obtaining the necessary approvals. Cook is
probably right; but the debate is beside the point. The
significance of the provision in the contract between Cook
and ACS that assigns to ACS the task of obtaining regula-
tory approvals is merely as further evidence that the
contract actually assigned the sale of paclitaxel to ACS,
because ACS did everything except the coating to bring
the paclitaxel to market.
  So Cook broke its contract with BSC and the next ques-
tion is the propriety of the relief granted by the district
court. As BSC points out, it would be very difficult for
a court to estimate the damages that it has incurred as a
result of Cook’s breach. The reason is that neither party
12                                                 No. 02-3740

has yet obtained the FDA’s approval to sell its product.
The de facto assignment to ACS undoubtedly gave Cook
a leg up, but to translate this insight into a dollar amount
of lost expected profits to BSC is impossible. No one
knows whether or when, as a consequence of the assign-
ment, Cook will obtain FDA approval or how well its
product will succeed in the market. No one knows wheth-
er or when BSC will obtain approval of its paclitaxel-
coated stent and how successful that product will be in
the market. There is injury to BSC in a probabilistic sense—
enough injury to establish standing and entitle it to relief
of some sort—but whether the injury will prove to be $1
or $100 million is unknown and unknowable.
   When a breach of contract is proved but damages can-
not be estimated with reasonable certainty, the plaintiff
is entitled to an injunction. But the injunction the dis-
trict court issued goes too far. It not only forbids Cook
to perform its contract with ACS or otherwise to violate
its contract with Angiotech and BSC; it also provides
that “no information, data or technology generated or
gathered in connection with the ACS deal shall be used for
any commercial purpose, including the purpose of obtain-
ing regulatory approval to sell paclitaxel-coated stents in the
United States or elsewhere.” The passage that we have itali-
cized violates the principle that in determining the appro-
priate scope of an injunction the judge must give due
weight to the injunction’s possible effect on innocent
third parties. Association of Community Organizations for
Reform Now v. Edgar, 56 F.3d 791, 797 (7th Cir. 1995); Kasper
v. Board of Election Commissioners, 814 F.2d 332, 340 (7th
Cir. 1987). In this case they are the sufferers from atheroscle-
rosis who might benefit from a device that prevents
restenosis. Those effects must be balanced against the
harm to BSC from narrowing the injunction by lancing
the italicized phrase—but as it happens that harm is zero
No. 02-3740                                             13

in a legal sense of “harm,” which differs from harm in
the lay sense. The difference is brought out in the legal
slogan damnum absque injuria, i.e., harm without a legally
cognizable injury.
  What would harm BSC in a legal sense would be the
competitive impact on it of having to compete with the
Cook-assisted ACHIEVE stent system; it would not be the
regulatory approval of that sale if the injunction against
sale remained in place so that Cook could not use the
approval to enable ACS to sell ACHIEVE in competi-
tion with BSC. When pressed at argument BSC’s lawyer
named only one harm to BSC from the grant of such
approval itself—and that a shocker: that the FDA might
discover in the course of considering Cook’s applica-
tion (prosecuted on its behalf by ACS) for approval that
paclitaxel-coated stents are harmful or ineffective, and
that the discovery would hurt BSC, whose own product
is also paclitaxel-coated. Indeed it would—and should.
We shall therefore modify the district court’s injunction
by striking the italicized phrase.
  Should Cook obtain the FDA’s approval before BSC
does, it will, as we have been at pains to emphasize, still
be enjoined from selling its product though authorized
by the FDA to do so. But at that point we imagine that
the parties will be able to negotiate the dissolution of
the injunction on terms that compensate BSC for having
been beaten to the punch. Of course, this suggests that
Cook will derive a commercial advantage from being
able to continue seeking the FDA’s approval to sell a
product that Cook is enjoined from selling. But that advan-
tage, which will in any event be shared with BSC in the
terms of settlement, seems slight in relation to the social
costs of delaying the process of FDA approval. Indeed,
should the negotiations we envisage (on the assump-
14                                                 No. 02-3740

tion that Cook obtains the FDA’s approval before BSC
does) fail, the district court might well decide to modify the
injunction so that people suffering from atherosclerosis
can obtain the benefit of Angiotech’s technology at the
earliest possible opportunity. See Fed. R. Civ. P. 60(b)(5);
Protectoseal Co. v. Barancik, 23 F.3d 1184, 1185-87 (7th Cir.
1994); In re Hendrix, 986 F.2d 195, 198 (7th Cir. 1993);
Bellevue Manor Associates v. United States, 165 F.3d 1249,
1255-56 (9th Cir. 1999); Alexis Lichine & Cie v. Sacha A. Lichine
Estate Selections, Ltd., 45 F.3d 582, 585-86 and n. 2 (1st Cir.
1995). While Cook errs in suggesting that 35 U.S.C.
§ 271(e)(1), which broadens the experimental-use de-
fense to patent infringement as explained in SmithKline
Beecham Corp. v. Apotex Corp., 247 F. Supp. 2d 1011, 1018
(N.D. Ill. 2003), is a defense to a breach of contract suit
(the provision is expressly limited to patent infringement
suits), the section does reflect a policy of allowing the use
of patented technology to obtain regulatory approval of
noninfringing technologies. There is no suggestion that in
using paclitaxel to obtain FDA approval Cook would be
infringing Angiotech’s patent. And so the policy that we
have just mentioned is something the district court
could and should consider if it is ever asked to modify the
injunction to enable paclitaxel to be made available to
the public.
  One loose end remains to be tied up. In the course of
the limited discovery that took place before the district
court granted summary judgment in favor of BSC, Cook
inadvertently turned over to BSC documents that were
privileged. The judge held that the disclosure waived
privilege, but he did not consider the documents in mak-
ing his decision, and BSC has since returned them to
Cook. Cook argues that the judge erred, but acknowl-
edges that the argument is moot unless we reverse
the finding of liability and remand for proceedings in
No. 02-3740                                                15

which the documents might unless privileged be used by
BSC as evidence against Cook. The documents relate to
liability rather than to relief and so their admissibility is
indeed a moot point.
  The judgment, as modified to narrow the injunction, is
affirmed.

A true Copy:
       Teste:

                       ________________________________
                           Clerk of the United States Court of
                             Appeals for the Seventh Circuit




                   USCA-02-C-0072—6-19-03
